How do smoking cessation medicines compare with respect to their neuropsychiatric safety? A protocol for a systematic review, network meta-analysis and cost-effectiveness analysis.

Thomas, K.H., Caldwell, D., Dalili, M.N. et al. (4 more authors) (2017) How do smoking cessation medicines compare with respect to their neuropsychiatric safety? A protocol for a systematic review, network meta-analysis and cost-effectiveness analysis. BMJ Open, 7 (6). e015414.

Abstract

Metadata

Authors/Creators:
  • Thomas, K.H.
  • Caldwell, D.
  • Dalili, M.N.
  • Gunnell, D.
  • Munafò, M.R.
  • Stevenson, M.
  • Welton, N.J.
Copyright, Publisher and Additional Information: © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
Keywords: bupropion; electronic cigarettes; network meta-analysis; nicotine replacement therapy; smoking cessation; varenicline
Dates:
  • Accepted: 19 April 2017
  • Published (online): 17 June 2017
  • Published: 1 June 2017
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Depositing User: Symplectic Sheffield
Date Deposited: 28 Jun 2017 08:48
Last Modified: 28 Jun 2017 08:48
Published Version: https://doi.org/10.1136/bmjopen-2016-015414
Status: Published
Publisher: BMJ Publishing Group
Refereed: Yes
Identification Number: https://doi.org/10.1136/bmjopen-2016-015414
Related URLs:

Share / Export

Statistics